Clinical Experience with Aurora Kinase Inhibitors: A Review

  • Boss D
  • Beijnen J
  • Schellens J
89Citations
Citations of this article
115Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The aurora kinase family of serine/threonine kinases comprises three members, designated auroras A, B, and C. Auroras A and B are essential components of the mitotic pathway, ensuring proper chromosome assembly, formation of the mitotic spindle, and cytokinesis. The role of aurora C is less clear. Overexpression of aurora A and B has been observed in several tumor types, and has been linked with a poor prognosis of cancer patients. Several small molecules targeting aurora kinases A and B or both have been evaluated preclinically and in early phase I trials. In this review we aim to summarize the most recent advances in the development of aurora kinase inhibitors, with a focus on the clinical data.

Cite

CITATION STYLE

APA

Boss, D. S., Beijnen, J. H., & Schellens, J. H. M. (2009). Clinical Experience with Aurora Kinase Inhibitors: A Review. The Oncologist, 14(8), 780–793. https://doi.org/10.1634/theoncologist.2009-0019

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free